201 related articles for article (PubMed ID: 30870475)
1. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
[TBL] [Abstract][Full Text] [Related]
2. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
Conti RM; Nikpay SS; Buntin MB
JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
[TBL] [Abstract][Full Text] [Related]
3. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
4. A Hepatitis C Treatment Program Based in a Safety-Net Hospital Patient-Centered Medical Home.
Lasser KE; Heinz A; Battisti L; Akoumianakis A; Truong V; Tsui J; Ruiz G; Samet JH
Ann Fam Med; 2017 May; 15(3):258-261. PubMed ID: 28483892
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
Zeta LM
Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
[TBL] [Abstract][Full Text] [Related]
6. Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States.
Malouin RA; Mckernan L; Forsberg A; Cheng D; Drake J; McLaughlin K; Trujillo M
Matern Child Health J; 2018 Sep; 22(9):1240-1246. PubMed ID: 29948762
[TBL] [Abstract][Full Text] [Related]
7. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
Health Resources and Services Administration, Department of Health and Human Services (HHS)
Fed Regist; 2017 Jan; 82(3):1210-30. PubMed ID: 28071875
[TBL] [Abstract][Full Text] [Related]
8. The unintended consequences of the 340B safety-net drug discount program.
Thomas S; Schulman K
Health Serv Res; 2020 Apr; 55(2):153-156. PubMed ID: 32114714
[No Abstract] [Full Text] [Related]
9. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
[TBL] [Abstract][Full Text] [Related]
10. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
Conti RM; Bach PB
Health Aff (Millwood); 2014 Oct; 33(10):1786-92. PubMed ID: 25288423
[TBL] [Abstract][Full Text] [Related]
11. Ensuring access to prescription medications in the post-ACA healthcare access landscape: the essential role of FQHCs in the safety net for the underinsured.
Shi L; Wharton MK; Monnette A
Am J Manag Care; 2018 Mar; 24(5 Suppl):S67-S73. PubMed ID: 29620813
[TBL] [Abstract][Full Text] [Related]
12. The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
Clark BL; Hou J; Chou CH; Huang ES; Conti R
Health Aff (Millwood); 2014 Nov; 33(11):2012-7. PubMed ID: 25367997
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
[TBL] [Abstract][Full Text] [Related]
14. Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.
Li Y; Xu S
JAMA Netw Open; 2022 Feb; 5(2):e220045. PubMed ID: 35179584
[TBL] [Abstract][Full Text] [Related]
15. Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
Mulligan K; Romley JA; Myerson R
BMC Res Notes; 2021 Jun; 14(1):228. PubMed ID: 34082835
[TBL] [Abstract][Full Text] [Related]
16. Consequences of the 340B Drug Pricing Program.
Desai S; McWilliams JM
N Engl J Med; 2018 Feb; 378(6):539-548. PubMed ID: 29365282
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed Literature.
Levengood TW; Conti RM; Cahill S; Cole MB
Milbank Q; 2024 Jun; 102(2):429-462. PubMed ID: 38282421
[TBL] [Abstract][Full Text] [Related]
18. Role of the 340B Drug Discount Program in Recent Cancer Care Trends.
Kantarjian HM; Chapman R
J Oncol Pract; 2015 Jul; 11(4):303-7. PubMed ID: 26036268
[TBL] [Abstract][Full Text] [Related]
19. Using 340B drug discounts to provide a financially sustainable medication discharge service.
Wu T; Williams C; Vranek K; Mattingly TJ
Res Social Adm Pharm; 2019 Jan; 15(1):114-116. PubMed ID: 29606609
[TBL] [Abstract][Full Text] [Related]
20. The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.
Ruley M; Belcher M; Sayre H; Coustasse A
Health Care Manag (Frederick); 2019; 38(4):311-321. PubMed ID: 31663869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
